Navigation Links
Early clinical data show galeterone safe, effective against prostate cancer
Date:3/31/2012

CHICAGO Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading the androgen receptor protein.

"This drug has a novel combined mechanism of action," said co-lead researcher R. Bruce Montgomery, M.D., associate professor of medical oncology at the University of Washington School of Medicine in Seattle, Wash. "Cancer cells are sly and mutate to get around drugs. The fact that this drug hits the prostate cancer cell in three different ways may help prevent resistance. It is a well-tolerated drug that could potentially be more effective than drugs we have now."

In the ARMOR1 study, Montgomery and colleagues assigned 49 patients with CRPC to one of eight dose regimens in single or split oral escalation doses of 650 mg, 975 mg, 1,300 mg, 1,950 mg or 2,600 mg every day for 12 weeks. None of the patients had received chemotherapy for their prostate cancer.

Researchers reported that no patients reached a maximum tolerated dose. Most side effects were minor and included fatigue, nausea and diarrhea. Researchers observed transient, nonserious elevated liver function tests in 15 patients, many of whom were asymptomatic. Eleven of these patients temporarily stopped galeterone treatment, and six returned to treatment with no recurring liver function test elevations. One serious complication occurred involving rhabdomyolysis in the setting of simvastatin therapy and underlying renal insufficiency.

In early efficacy tests, 49 percent of patients had prostate-specific antigen (PSA) reductions of 30 percent or more; 11 of these patients had reductions of 50 percent or more. In addition, CT scans revealed reduction in tumor size for some patients.

"Because the androgen receptor controls PSA expression, improved PSA response shows that the drug is getting to the target," said Montgomery. "For the majority of patients, to reduce their PSAs by 30 percent or more is quite good in a phase I dose-finding trial."

Researchers will investigate long-term safety and an assessment of efficacy in a phase II study that Tokai Pharmaceuticals has planned for the second half of 2012.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007
2. Moms Lifestyle in Early Pregnancy Affects Babys Size
3. Early life stress may predict cardiovascular disease
4. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
5. Alzheimers Association Applauds Social Security Administration for Adding Early-Onset Alzheimers to Its Compassionate Allowances Initiative
6. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
7. JCI online early table of contents: Feb. 15, 2010
8. 29 Clear Channel stations Nationwide Raise Nearly $2.8 Million to Help Save the Lives of Kids Fighting Cancer and Other Deadly Diseases
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Early On, Hormone Therapy May Raise Womens Heart Risks
11. FriendsofWater.com Responds to the National Acadamy of Sciences Report that Millions of Americans Get Sick Yearly from Contaminated Water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 2016 , ... University of the People, the world’s first ... Associates and Bachelor's degrees in Health Studies. Leading figures are heading the program’s ... Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, Stanley M. Bergman; ...
(Date:5/3/2016)... GA (PRWEB) , ... May 03, 2016 , ... Nationally recognized personal injury law firm ... Day weekend by giving free roses to anyone who wants one for their Mother or ... we recognize the important valuable contributions of Mothers.” Monge goes on to say, “we ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... advisory organization, announces Benefits Alliance Insurance Services as the latest addition to its ... California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The ...
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic ... treatments to both new and existing patients. Cosmetic dentistry allows patients to improve the ... have healthy smiles with some minor or more serious cosmetic flaws. These specials allow ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Microsoft secure remote access connectivity solutions, today announced the new SecureAccess feature ... DirectAccess. The new Celestix SecureAccess release will enable organizations to get the ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... Research and Markets has announced ... Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected to ... 2016-2020. , ,The growing adoption of laser in aesthetics ... the market. Lasers are used to treat a broad ...
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
Breaking Medicine Technology: